Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
|Videos|November 19, 2013
The Developmental Process of MK-3475 in Melanoma
Author(s)Antoni Ribas, MD, PhD
Antoni Ribas, MD, PhD, discusses the development process of PD-1 antibody MK-3475 in melanoma.
Advertisement
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the development process of PD-1 antibody MK-3475 in melanoma.
Clinical Pearls
- MK-3475 has gone through phase I testing
- Physicians are eagerly awaiting data from a phase II clinical trial comparing chemotherapy to MK-3475 in patients who have previously received ipilimumab
- A trial studying two dosing regimens of MK-3475 compared to ipilimumab in frontline therapy for patients with metastatic melanoma is currently accruing
- MK-3475 is also being developed in other cancers, such as lung, bladder, and head and neck
Advertisement
Related to this article
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sørbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5